Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV
NCT ID: NCT07054931
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
48 participants
INTERVENTIONAL
2025-09-05
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
NCT04586673
Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART
NCT01024842
HIV Vaccine Study in HIV Positive Patients
NCT01071031
Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63
NCT00369031
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
NCT06071767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Participants in Arm A will undergo a period of treatment interruption induced viraemia followed by two infusions of broadly neutralising antibodies (GS-5423 and GS-2872). They will then stop ART for an analytical treatment interruption period to determine the clinical impact and to measure how long before any HIV virus returns to the blood.
GS-5423
Solution for infusion 2550 mg Arm A, Arm B and Arm C
GS-2872
Solution for infusion 850 mg Arm A, Arm B and Arm C
Treatment interruption induced viraemia
Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
Arm B
Participants in Arm B will receive a combination of three HIV vaccines (one prime dose (ChAdOx1.tHIVconsv1 and ChAdOx1.HIVconsv62) followed by two booster doses of MVA.tHIVconsv4 at 4 weeks and 16 weeks), followed by two infusions of broadly neutralising antibodies, GS-5423 and GS-2872. They will then stop ART for an analytical treatment interruption period to determine the clinical impact and to measure how long before any HIV virus returns to the blood.
ChAdOx1.tHIVconsv1
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
ChAdOx1.HIVconsv62
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
MVA.tHIVconsv4
suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
GS-5423
Solution for infusion 2550 mg Arm A, Arm B and Arm C
GS-2872
Solution for infusion 850 mg Arm A, Arm B and Arm C
Arm C
Participants in Arm C will undergo a period of treatment interruption induced viraemia followed by a combination of three HIV vaccines (one prime dose (ChAdOx1.tHIVconsv1 and ChAdOx1.HIVconsv62) followed by two booster doses of MVA.tHIVconsv4 at 4 weeks and 16 weeks), followed by two infusions of broadly neutralising antibodies, GS-5423 and GS-2872. They will then stop ART for an analytical treatment interruption period to determine the clinical impact and to measure how long before any HIV virus returns to the blood.
ChAdOx1.tHIVconsv1
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
ChAdOx1.HIVconsv62
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
MVA.tHIVconsv4
suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
GS-5423
Solution for infusion 2550 mg Arm A, Arm B and Arm C
GS-2872
Solution for infusion 850 mg Arm A, Arm B and Arm C
Treatment interruption induced viraemia
Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ChAdOx1.tHIVconsv1
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
ChAdOx1.HIVconsv62
solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
MVA.tHIVconsv4
suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
GS-5423
Solution for infusion 2550 mg Arm A, Arm B and Arm C
GS-2872
Solution for infusion 850 mg Arm A, Arm B and Arm C
Treatment interruption induced viraemia
Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed written consent including consent to long-term follow-up
* Willing and able to comply with visit schedule and provide blood sampling
* Willing to consent to their HIV care team being informed of their participation and sharing relevant clinical information
* Stable on oral ART with suppressed undetectable HIV pVL 'target not detected' (TND) using local assays for ≥ 1 years (a single viral load measurement \>50 but \<500 copies/ml during this time period is allowable)
* No evidence of viral insensitivity to GS-2872 based on proviral sequencing
* No significant co-morbidities according to the investigator's opinion
* Nadir CD4 \>200 cells/µl unless treatment commenced during documented acute seroconversion
* Current CD4 count \>500 cells/µl or CD4:CD8 ratio \>1.0
* On integrase inhibitor (INSTI) or boosted protease inhibitor (bPI) based regimen at time of randomisation. If previously on non-nucleoside reverse transcriptase inhibitor (NNRTI) must have switched at least 4 weeks prior to randomisation
* Adequate haemoglobin (Hb ≥12 g/dL for males, ≥11 g/dL for females)
* Weight ≥ 50kg
* Has received at least 3 doses of vaccination against coronavirus (COVID-19), at least 4 weeks prior to randomisation
* Has received current seasonal vaccination against Influenza\*
* People of childbearing potential\*\* must agree to use hormonal contraception, intrauterine device, intrauterine hormone-releasing system, or otherwise practice complete abstinence\*\*\* from at least two weeks before the first Investigational Medicinal Product (IMP) administration, for at least 20 months after the last IMP administration, and until undetectable viral load on ART
* All participants must agree to take precautions to prevent onward transmission of HIV (such as condoms or PrEP) whilst they are off ART and/or have a detectable viral load \* Applicable during Influenza season (September-April inclusive). \*\*Individuals capable of becoming pregnant are defined as those who are fertile, with childbearing reproductive organs, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Permanent sterilisation of the participant's sole partner (e.g. vasectomy) is also accepted.
A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in those not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
\*\*\*Complete abstinence (defined as refraining from heterosexual intercourse) must be in line with the preferred and usual lifestyle of the participant. Barrier contraception, periodic abstinence (e.g. calendar, ovulation, symptothermal, post ovulation methods), withdrawal and progestogen-only oral hormonal contraception where inhibition of ovulation is not the primary mode of action are not acceptable methods of contraception.
Exclusion Criteria
* Any current or past history of malignancy, excluding squamous cell skin cancers
* Concurrent opportunistic infection or other co-morbidity likely to occur during the trial e.g.
malabsorption syndromes, autoimmune disease
* Any contraindication to receipt of BHIVA recommended combination antiretrovirals
* Current treatment with injectable ART
* HTLV-1 co-infection
* Any evidence of major antiretroviral resistance mutations
* Evidence of HBV infection requiring treatment (HBsAg+, or HBcAb+ without HBsAb+)
* Evidence of HCV infection (HCVAg+ and/or HCV RNA detected)
* Individuals at high risk from severe Covid-19 disease who may be defined in accordance with NHSE guidance as vulnerable and shielded (as per the view of participant's physician)
* Current or planned systemic immunosuppressive therapy (inhaled and topical corticosteroids are allowed)
* Participation in another research study involving receipt of an investigational medicinal product (IMP) in the 3 months preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period (concurrent observational studies are allowed)
* History of anaphylaxis or severe adverse reaction to antibody infusions, or hypersensitivity to GS-2872 or GS-5423 or to any constituent products or excipients thereof
* History of anaphylaxis or severe adverse reaction to any previous vaccine
* A history of thrombosis with thrombocytopaenia syndrome (TTS) following vaccination with any adenoviral vector vaccines
* A history of anti-phospholipid syndrome
* A history of heparin-induced thrombocytopenia
* A history of cerebral venous sinus thrombosis
* Any history of other bleeding or clotting disorders of clinical significance according to the investigator's discretion
* Known anti-PF4 antibody positivity
* Treatment with IV immunoglobulin or other monoclonal antibody treatments planned during the duration of the trial
* Clinically significant abnormal blood test results at screening including
1. Moderate to severe hepatic impairment as defined by significant liver impairment with evidence of advanced fibrosis or cirrhosis with decompensation
2. ALT \>5 x ULN
3. eGFR \<601
4. uPCR \>30 mg/mmol
5. INR \>1.5
* Evidence of organ dysfunction or any clinically significant deviation from normal in medical history, physical examination and/or vital signs that the investigator believes is a preclusion from enrolment into the study
* Active alcohol or substance use that, in the investigator's opinion, will prevent adequate adherence with study requirements
* Insufficient venous access that will allow scheduled blood draws as per protocol
* Concern regarding likelihood of participant not taking precautions to prevent HIV transmission during treatment interruption period
* Pregnancy, lactation or intending to become pregnant
* Participants unable to be followed closely for geographic, social or psychological reasons
* Participants unable to adequately understand written or verbal English to appropriately consent to the study
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guys and St Thomas' NHS Trust
London, , United Kingdom
St Mary's Clinical Trial Unit
London, , United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR/Y008847/1
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
AbVax
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.